The utility of thromboelastometry in prophylactic platelet transfusion for hematological malignancies

被引:16
|
作者
Akay, Olga Meltem [1 ]
Sahin, Deniz Goren [1 ]
Andic, Neslihan [1 ]
Gunduz, Eren [1 ]
Karagulle, Mustafa [1 ]
Colak, Ertugrul [2 ]
Gulbas, Zafer [3 ]
机构
[1] Eskisehir Osmangazi Univ, Sch Med, Dept Hematol, TR-26480 Eskisehir, Turkey
[2] Eskisehir Osmangazi Univ, Sch Med, Dept Biostat, TR-26480 Eskisehir, Turkey
[3] Anatolia Hlth Ctr, Bone Marrow Transplantat Ctr, Gebze, Turkey
关键词
Platelet; Thromboelastometry; Transfusion; RANDOMIZED CONTROLLED-TRIAL; ACUTE-LEUKEMIA; CLINICAL-PRACTICE; FACTOR-VIIA; IN-VITRO; PLASMA; CANCER; THROMBOCYTOPENIA; RECOMMENDATIONS; COAGULATION;
D O I
10.1016/j.transci.2015.03.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is still debate on how, platelet transfusions should be used to prevent severe bleeding. The aim of our study is to assess the clinical efficacy of thromboelastometry in reducing number of prophylactic platelet transfusions in patients with hematological malignancies. One hundred hematological malignancy patients were included in the study. Six units random donor platelets (RDPs) was given to the first group, three units RDPs was given to the second group, one unit single donor platelets (SDPs) was given to the third group, and 1/2 unit SDPs was given to the fourth group. Before and 15 minutes after transfusion, rotation thromboelastometry (ROTEM) was performed (Pentapharm GmbH, Munich, Germany). ROTEM parameters did not show any statistical difference between 'low dose' and 'high dose' random or single donor platelet transfusions. Therefore, low dose platelet transfusion can be considered because of its reduced adverse transfusion reactions and economic burden. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:64 / 68
页数:5
相关论文
共 50 条
  • [21] CONTROVERSIES IN TRANSFUSION MEDICINE - PROPHYLACTIC PLATELET TRANSFUSION THERAPY - PRO
    BAER, MR
    BLOOMFIELD, CD
    TRANSFUSION, 1992, 32 (04) : 377 - 380
  • [23] Should total platelet mass be a criterion for prophylactic platelet transfusion?
    Aster, Richard H.
    TRANSFUSION, 2009, 49 (10) : 2014 - 2015
  • [24] Platelet transfusion as prophylactic treatment in thrombocytopenia.
    Ferrara, M
    Matarese, SMR
    Borrelli, B
    Coppola, A
    Coppola, L
    Chiariello, S
    Esposito, L
    BLOOD, 1999, 94 (10) : 248A - 248A
  • [25] Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation
    Desborough, Michael
    Estcourt, Lise J.
    Doree, Carolyn
    Trivella, Marialena
    Hopewell, Sally
    Stanworth, Simon J.
    Murphy, Michael F.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (08):
  • [26] Update on the Role and Utility of Extracellular Vesicles in Hematological Malignancies
    Bazzoni, Riccardo
    Tanasi, Ilaria
    Turazzi, Nice
    Krampera, Mauro
    STEM CELLS, 2022, 40 (07) : 619 - 629
  • [27] Platelet transfusions in advanced hematological malignancies: A position paper
    Lassauniere, JM
    Bertolino, M
    Hunault, M
    Zittoun, R
    Verspieren, P
    MohKlaren, J
    Jaulmes, D
    Colombat, P
    JOURNAL OF PALLIATIVE CARE, 1996, 12 (01) : 38 - 41
  • [28] Rh(D)-incompatible platelet transfusion in hematological patients
    Cid, J
    Ortin, X
    Elies, E
    Castellà, D
    Panadés, M
    Martin-Vega, C
    TRANSFUSION, 2001, 41 (09) : 12S - 12S
  • [29] Granulocyte transfusion in the management of patients with hematological malignancies and severe infection
    Cherif, H.
    Axdorph, U.
    Kalin, M.
    Bjorkholm, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 23 - 23
  • [30] Shifting ground and gaps in transfusion support of patients with hematological malignancies
    Cserti-Gazdewich, Christine
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2018, : 553 - 560